Back to Search
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Patients With Traumatic Brain Injury
Tuscaloosa, Alabama, 35404
Scottsdale, Arizona, 85254
Seattle, Washington, 98108
Salem, Virginia, 24153
Richmond, Virginia, 23298
Scottsdale, Arizona, 85254
Seattle, Washington, 98108
Salem, Virginia, 24153
Richmond, Virginia, 23298
Search ended 09/28/2022
This is a multicenter, randomized, placebo-controlled study to evaluate AVP-786 for the treatment of neurobehavioral disinhibition including aggression, agitation, and irritability in participants with traumatic brain injury (TBI).
Eligibility
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, learn about Clinical
| Ages Eligible for Study | Min Age: 18 years - Max Age: 75 years |
| Sexes Eligible for Study | Female |
| Accepts Healthy Volunteers | Yes |
Visit ClinicalTrials.Gov for more information
Support nonprofit organizations through participating in clinical trials at no cost to you
You may also be interested in
Pelham, Alabama and more
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
Cytomegalovirus Infection Read more
Hollywood, Florida and more
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-Year-Old Healthy Adults
Epstein-Barr Virus Infection Read more
Rockville, Maryland and more